Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and α vβ 3 integrin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 34, 2011, Pages 14067-14072

  Papo, Niv ^a   Silverman, Adam P ^a   Lahti, Jennifer L ^a   Cochran, Jennifer R ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

Bispecific protein; Directed evolution; Protein engineering; Yeast surface display

Indexed keywords

ALPHA2B BETA3 INTEGRIN; ALPHAVBETA5 INTEGRIN; INTEGRIN; MATRIGEL; MOLECULAR SCAFFOLD; MUTANT PROTEIN; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VITRONECTIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BINDING ASSAY; CAPILLARY TUBE FORMATION; CAPILLARY WALL; CELL CULTURE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIMERIZATION; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENETIC ENGINEERING; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; RECEPTOR DIMERIZATION; SURFACE PLASMON RESONANCE;

CELL LINE; ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; KINETICS; LIGANDS; MUTANT PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 80052184184     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1016635108     Document Type: Article

References (42)

1. Somanath PR, Ciocea A, Byzova TV (2009) Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys 53:53-64.
2. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611.
3. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-478. (Pubitemid 46823443)
4. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alphav beta3 for angiogenesis. Science 264:569-571.
5. Stupack DG, Cheresh DA (2004) Integrins and angiogenesis. Curr Top Dev Biol 64:207-238. (Pubitemid 39752398)
6. Byzova TV, et al. (2000) A mechanism for modulation of cellular responses to VEGF: Activation of the integrins. Mol Cell 6:851-860.
7. De S, et al. (2005) VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA 102:7589-7594.
8. Kim TJ, et al. (2009) Combined anti-angiogenic therapy against VEGF and integrin alphav beta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther 8:2263-2272.
9. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV (2007) Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 101:570-580. (Pubitemid 351325874)
10. Serini G, Napione L, Arese M, Bussolino F (2008) Besides adhesion: New perspectives of integrin functions in angiogenesis. Cardiovasc Res 78:213-222. (Pubitemid 351556107)
11. Soldi R, et al. (1999) Role of alphav beta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 18:882-892. (Pubitemid 29082268)
12. 3 and VEGFR2 in angiogenesis. Angiogenesis 12:177-185.
13. v-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. Int J Cancer 119:423-431.
14. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31.
15. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286.
16. Eskens FA (2004) Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 90:1-7.
17. Ferrara N, Mass RD, Campa C, Kim R (2007) Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58:491-504. (Pubitemid 46706529)
18. Tucker GC (2006) Integrins: Molecular targets in cancer therapy. Curr Oncol Rep 8:96-103.
19. Stupp R, Ruegg C (2007) Integrin inhibitors reaching the clinic. J Clin Oncol 25:1637-1638. (Pubitemid 46797938)
20. Reynolds AR, et al. (2004) Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res 64:8643-8650. (Pubitemid 39552078)
21. Reynolds AR, et al. (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15:392-400.
22. Muller YA, et al. (1997) Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 94:7192-7197. (Pubitemid 27345291)
23. Wiesmann C, et al. (1997) Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91:695-704. (Pubitemid 27513660)
24. Xiong JP, Stehle T, Goodman SL, Arnaout MA (2003) Integrins, cations and ligands: Making the connection. J Thromb Haemost 1:1642-1654.
25. Luo BH, Carman CV, Springer TA (2007) Structural basis of integrin regulation and signaling. Annu Rev Immunol 25:619-647. (Pubitemid 46697919)
26. Kowanetz M, Ferrara N (2006) Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res 12:5018-5022. (Pubitemid 44453326)
27. Hynes RO (2002) Integrins: Bidirectional, allosteric signaling machines. Cell 110:673-687.
28. Fuh G, Li B, Crowley C, Cunningham B, Wells JA (1998) Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 273:11197-11204. (Pubitemid 28204970)
29. Siemeister G, et al. (1998) An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc Natl Acad Sci USA 95:4625-4629. (Pubitemid 28207963)
30. Boesen TP, Soni B, Schwartz TW, Halkier T (2002) Single-chain vascular endothelial growth factor variant with antagonist activity. J Biol Chem 277:40335-40341. (Pubitemid 35215606)
31. Maeshima Y, Colorado PC, Kalluri R (2000) Two RGD-independent alphav beta3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275:23745-23750. (Pubitemid 30624661)
32. Popkov M, et al. (2004) Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. J Immunol Methods 288:149-164. (Pubitemid 38739260)
33. Huang X, Gottstein C, Brekken RA, Thorpe PE (1998) Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. Biochem Biophys Res Commun 252:643-648. (Pubitemid 28556830)
34. Kleinman HK, et al. (1986) Basement membrane complexes with biological activity. Biochemistry 25:312-318. (Pubitemid 16053790)
35. Passaniti A, et al. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 67:519-528.
36. Cochran JR (2010) Engineered proteins pull double duty. Sci Transl Med 2:17ps15.
37. Fischer N, Leger O (2007) Bispecific antibodies: Molecules that enable novel therapeutic strategies. Pathobiology 74:3-14.
38. Kufer P, Lutterbuse R, Baeuerle PA (2004) A revival of bispecific antibodies. Trends Biotechnol 22:238-244. (Pubitemid 38515741)
39. Haas TA, Plow EF (1994) Integrin-ligand interactions: A year in review. Curr Opin Cell Biol 6:656-662. (Pubitemid 24295298)
40. Keyt BA, et al. (1996) Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271:5638-5646.
41. Gerber HP, et al. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3?-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343.
42. Blechman JM, et al. (1995) The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80:103-113.